The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies.
This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2005 to mid 2011.
The report provides a detailed understand and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all co-promotion and co-marketing deals announced since 2005 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of co-promotion and co-marketing dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst
Chapter 2 provides an analysis of the trends in co-promotion and co-marketing as well as a discussion on the merits of each type of deal.
Chapters 3 and 4 provide an overview of the structure of co-promotion and co-marketing deals, respectively. Each chapter includes numerous case studies to enable understanding of both pure co-promotion/marketing deals and multicomponent deals where co-promotion/marketing forms a part.
Chapters 5 and 6 provide a review of the leading co-promotion and co-marketing deals since 2000, respectively. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 7 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of co-promotion and co-marketing contract deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapters 8 and 9 provide a comprehensive and detailed review of co-promotion and co-marketing deals signed and announced since 2005. Each chapter is organized by A-Z, stage of development at signing, and therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report also includes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing dealmaking since 2000.
In conclusion, this report provides everything a prospective dealmaker needs to know about co-promotion and co-marketing as an opportunity to participate in the commercialization of either candidate compounds in development or products already on the market.
TABLE OF CONTENT
Chapter 1 - Introduction
Chapter 2 - Trends in co-promotion and co-marketing dealmaking
2.2. Difference between co-promotion and co-marketing deals
2.3. Trends in co-promotion deals since 2000
2.4. Trends in co-marketing deals since 2000
2.4.1. When co-marketing can be useful
2.4.2. When co-marketing is the only option
2.5. Pure deals and multi-component deals
2.5.1. Attributes of pure co-promotion deals
2.5.2. Attributes of co-promotion in multi-component deals
2.6. Reasons for including co-promotion options in a deal
2.7. Uptake of co-promotion rights
2.8. Co-promotion rights as bargaining chips
2.9. Aligning partners to make the co-promote work
2.10 The future of co-promotion as part of multicomponent deals
Chapter 3 - Overview of co-promotion deal structure
3.2. Pure versus multi-component co-promotion deals
3.3. Pure co-promotion agreement structure
3.3.1. Example co-promotion agreements
3.3.1.a. Case study 1: GlaxoSmithKline - Allergan - September 2005
3.3.1.b. Case study 2: Cardinal Health - Bone Care - July 2004
3.4. Co-promotion rights as part of a wider alliance agreement
3.4.1. Example co-promotion option clauses
3.4.1.a. Case study 3: Novartis - Anadys - June 2005
3.4.1.b. Case study 4: AstraZeneca - Dynavax - September 2006
3.4.2. Example co-promotion right clauses
3.4.2.a. Case study 5: Gilead - Achillion - November 2004
3.4.2.b. Case study 6: Merck - Ariad - July 2007
3.5. Embedded co-promotion rights enabling third party engagement
3.5.1. Example co-promotion clauses enabling third party engagement
3.5.1.a. Case study 7: UCB - ImClone - August 2005
Chapter 4 - Overview of co-marketing deal structure
4.2. Co-marketing agreement structure
4.2.1. Example co-marketing agreements
4.2.1.a. Case study 8: Helix Biomedix - Body Blue Inc - November 2004
4.3. Co-marketing rights as part of a wider alliance agreement
4.3.1. Example co-marketing right clauses
4.3.1.a. Case study 9: Alcon - NovaCal - September 2006
Chapter 5 - Leading co-promotion deals
5.2. Top co-promotion deals by value
5.3. Top pure co-promotion deals
5.4. Top co-promotion deals signed by bigpharma
5.5. Most active co-promotion dealmakers
5.6. Bigpharma co-promotion deal activity
Chapter 6 - Leading co-marketing deals
6.2. Top co-marketing deals by value
6.3. Top pure co-marketing deals
6.4. Top co-marketing deals signed by bigpharma
6.5. Most active co-marketing dealmakers
6.6. Bigpharma co-marketing deal activity
Chapter 7 - Bigpharma co-promotion and co-marketing agreements
7.2. How to use co-promotion and co-marketing agreements
7.3. Company co-promotion and co-marketing agreement listings
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co
Chapter 8 - Co-promotion agreement directory 2005-2011
8.2. Company A-Z
8.3. By therapy area
Central nervous System
8.4. By stage of development at signing
Chapter 9 - Co-marketing agreement directory 2005-2011
9.2. Company A-Z
9.3. By therapy area
Central nervous System
9.4. By stage of development at signing
Appendix 1 - Co-promotion/co-marketing references
Appendix 2 - Resources
Appendix 3 - Deal type definitions
Appendix 4 - Example co-promotion contract document
Appendix 5 - Example co-marketing contract document
Recent report titles from CurrentPartnering
Order Form - Reports
Figure 1: Definition of co-promotion and co-marketing
Figure 2: Trends in co-promotion deal announcements, 2000-2011
Figure 3: Co-promotion deals signed at each phase of development, 2000-2011
Figure 4: Trends in co-marketing deal announcements, 2000-2011
Figure 5: Co-marketing deals signed at what phase of development, 2000-2011
Figure 6: Situations where co-marketing can prove useful
Figure 7: Pure versus multi-component co-promotion deal announcements, 2000-2011
Figure 8: Stage of development at which pure and multi-component co-promotion deals are announced 2000-2011
Figure 9: Pure versus multi-component co-marketing deal announcements, 2000-2011
Figure 10: Stage of development at which pure and multi-component co-marketing deals are announced 2000-2011
Figure 11: Key components of a pure co-promotion deal
Figure 12: Key components of a multi-component co-promotion deal
Figure 13: Example deals where co-promotion options have been actively exercised, since 2000
Figure 14: Issues in implementing co-promotion agreements
Figure 15: Co-promotion agreements - what should a contract include?
Figure 16: Components of the co-promotion deal structure
Figure 17: Components of the co-marketing deal structure
Figure 18: Top 50 co-promotion deals by value since 2000
Figure 19: Top 50 co-promotion deals signed by bigpharma value since 2000
Figure 20: Most active co-promotion dealmakers 2005-2011
Figure 21: Bigpharma - top 50 - co-promotion deals 2005 to 2011
Figure 22: Top co-marketing deals by value since 2000
Figure 23: Top co-marketing deals involving bigpharma by value since 2000
Figure 24: Most active co-marketing dealmakers 2005-2011
Figure 25: Bigpharma - top 50 - co-marketing deals since 2005
Figure 26: Online partnering resources
Figure 27: Deal type definitions
Figure 28: Co-promotion agreement between Bayer and Zymogenetics, June 2007
Figure 29: Co-development and co-marketing agreement between Roche and Alnylam Pharmaceuticals, November 2009